1920-59-RIS-LW ERDF Funded - ITT FOR a Matrix-assisted laser desorption ionization (MALDI) imaging Mass Spectrometer, micro Computerised Tomography (micro CT) scanner and Atomic Force Microscopy-Ra

The project is receiving up to £2.7M of funding from the England European Regional Development Fund as part of the European Structural and Investment Funds Growth Programme 2014-2020. The Ministry of Housing, Communities and Local Government (and in London the intermediate body Greater London Authority) is the Managing Authority for European Regional Development Fund. Established by the European Union, the European Regional Development Fund helps local areas stimulate their economic development by investing in projects which will support innovation, businesses, create jobs and local community regenerations. For more information visit www.gov.uk/european-growth-funding ↗

The Northern Powerhouse is a key aspect of this Government's approach to addressing the productivity gap in the North and ensuring a stronger, more sustainable economy for all parts of the UK. Alongside over €1.5 billion of European Regional Development Fund support for businesses and communities across the North, the government has awarded £3.4 billion in three rounds of Growth Deals across the Northern Powerhouse.

The likely use of the MALDI Mass Spectrometer will be in the analysis of molecules in a range of biological and chemical samples. Industry sectors that this will impact will be: Chemical manufacturers, pharmaceutical companies, forensic testing, agricultural product manufacturers and food & beverage companies. The benefits / likely outcomes are efficacy and safety testing of existing or new products (validated research materials for marketing purposes, compliance with product regulations). Also, identification of mode of action of products (novel used of existing products).

The likely use of the Integrated AFM-Raman Imaging System will be in biotech, pharmaceuticals, high precision engineering, NHS, and Private healthcare centres and SMEs developing new products.

The likely use of the MicroCT (Computerised Tomography) Scanner will be in private healthcare centres and SMEs developing bone implants for downstream analysis. Companies undertaking R&D in biomaterials and bone material science applications in geology and environmental analysis. The benefits / likely outcomes are development of new materials for bone formation and regeneration. Non-destructive analysis of implants and testing of novel drugs.

The medium to longer term objectives, year 2 onwards, include work with business and academic partners to:

• Develop new materials, products, and components; Improve existing products and processes; and increase performance and market opportunities for companies through improved product life, longevity, durability, usability and/or enhanced functionality. For example, the creation of more sustainable materials through the use of conductive material or ability to function in extreme environments.
• Increase competitiveness of UK and SCR companies in priority sectors, including manufacturing, health care technologies and devices.
• Increase the number of small and medium sized enterprises engaged in knowledge exchange and collaboration.
• Improve the commercialisation and market entry of new or enhanced products or services including by small and medium sized enterprises.
• Increase investment in research and innovation, including by small and medium sized enterprises.

The instruments, detailed above, will be used primarily to support business engagement activities, contract research and external consultancy. However as appropriate a wide range of other activities including academic research and taught practical classes for undergraduate and post-graduate courses will be supported.

Lots 1&2 are primarily for use by the Biomolecular Sciences Research Centre (BMRC), within the Industry and Innovation Research Institute (I2RI). Lot 3 is primarily for use by the Materials and Engineering Research Institute (MERI) also within I2RI.

The project is receiving up to £2.7M of funding from the England European Regional Development Fund as part of the European Structural and Investment Funds Growth Programme 2014-2020. The Ministry of Housing, Communities and Local Government (and in London the intermediate body Greater London Authority) is the Managing Authority for European Regional Development Fund. Established by the European Union, the European Regional Development Fund helps local areas stimulate their economic development by investing in projects which will support innovation, businesses, create jobs and local community regenerations. For more information visit www.gov.uk/european-growth-funding ↗

The Northern Powerhouse is a key aspect of this Government's approach to addressing the productivity gap in the North and ensuring a stronger, more sustainable economy for all parts of the UK. Alongside over €1.5 billion of European Regional Development Fund support for businesses and communities across the North, the government has awarded £3.4 billion in three rounds of Growth Deals across the Northern Powerhouse.

The likely use of the MALDI Mass Spectrometer will be in the analysis of molecules in a range of biological and chemical samples. Industry sectors that this will impact will be: Chemical manufacturers, pharmaceutical companies, forensic testing, agricultural product manufacturers and food & beverage companies. The benefits / likely outcomes are efficacy and safety testing of existing or new products (validated research materials for marketing purposes, compliance with product regulations). Also, identification of mode of action of products (novel used of existing products).

The likely use of the Integrated AFM-Raman Imaging System will be in biotech, pharmaceuticals, high precision engineering, NHS, and Private healthcare centres and SMEs developing new products.

The likely use of the MicroCT (Computerised Tomography) Scanner will be in private healthcare centres and SMEs developing bone implants for downstream analysis. Companies undertaking R&D in biomaterials and bone material science applications in geology and environmental analysis. The benefits / likely outcomes aredevelopment of new materials for bone formation and regeneration. Non-destructive analysis of implants and testing of novel drugs.

The medium to longer term objectives, year 2 onwards, include work with business and academic partners to:

• Develop new materials, products, and components; Improve existing products and processes; and increase performance and market opportunities for companies through improved product life, longevity, durability, usability and/or enhanced functionality. For example, the creation of more sustainable materials through the use of conductive material or ability to function in extreme environments.
• Increase competitiveness of UK and SCR companies in priority sectors, including manufacturing, health care technologies and devices.
• Increase the number of small and medium sized enterprises engaged in knowledge exchange and collaboration.
• Improve the commercialisation and market entry of new or enhanced products or services including by small and medium sized enterprises.
• Increase investment in research and innovation, including by small and medium sized enterprises.

The instruments, detailed above, will be used primarily to support business engagement activities, contract research and external consultancy. However as appropriate a wide range of other activities including academic research and taught practical classes for undergraduate and post-graduate courses will be supported.

Lots 1&2 are primarily for use by the Biomolecular Sciences Research Centre (BMRC), within the Industry and Innovation Research Institute (I2RI). Lot 3 is primarily for use by the Materials and Engineering Research Institute (MERI) also within I2RI.

The project is receiving up to £2.7M of funding from the England European Regional Development Fund as part of the European Structural and Investment Funds Growth Programme 2014-2020. The Ministry of Housing, Communities and Local Government (and in London the intermediate body Greater London Authority) is the Managing Authority for European Regional Development Fund. Established by the European Union, the European Regional Development Fund helps local areas stimulate their economic development by investing in projects which will support innovation, businesses, create jobs and local community regenerations. For more information visit www.gov.uk/european-growth-funding ↗

The Northern Powerhouse is a key aspect of this Government's approach to addressing the productivity gap in the North and ensuring a stronger, more sustainable economy for all parts of the UK. Alongside over €1.5 billion of European Regional Development Fund support for businesses and communities across the North, the government has awarded £3.4 billion in three rounds of Growth Deals across the Northern Powerhouse.

The likely use of the MALDI Mass Spectrometer will be in the analysis of molecules in a range of biological and chemical samples. Industry sectors that this will impact will be: Chemical manufacturers, pharmaceutical companies, forensic testing, agricultural product manufacturers and food & beverage companies. The benefits / likely outcomes are efficacy and safety testing of existing or new products (validated research materials for marketing purposes, compliance with product regulations). Also, identification of mode of action of products (novel used of existing products).

The likely use of the Integrated AFM-Raman Imaging System will be in biotech, pharmaceuticals, high precision engineering, NHS, and Private healthcare centres and SMEs developing new products.

The likely use of the MicroCT (Computerised Tomography) Scanner will be in private healthcare centres and SMEs developing bone implants for downstream analysis. Companies undertaking R&D in biomaterials and bone material science applications in geology and environmental analysis. The benefits / likely outcomes are development of new materials for bone formation and regeneration. Non-destructive analysis of implants and testing of novel drugs.

The medium to longer term objectives, year 2 onwards, include work with business and academic partners to:

• Develop new materials, products, and components; Improve existing products and processes; and increase performance and market opportunities for companies through improved product life, longevity, durability, usability and/or enhanced functionality. For example, the creation of more sustainable materials through the use of conductive material or ability to function in extreme environments.
• Increase competitiveness of UK and SCR companies in priority sectors, including manufacturing, health care technologies and devices.
• Increase the number of small and medium sized enterprises engaged in knowledge exchange and collaboration.
• Improve the commercialisation and market entry of new or enhanced products or services including by small and medium sized enterprises.
• Increase investment in research and innovation, including by small and medium sized enterprises.

The instruments, detailed above, will be used primarily to support business engagement activities, contract research and external consultancy. However as appropriate a wide range of other activities including academic research and taught practical classes for undergraduate and post-graduate courses will be supported.

Lots 1&2 are primarily for use by the Biomolecular Sciences Research Centre (BMRC), within the Industry and Innovation Research Institute